Added benefit of Jardiance not proven, says IQWiG

Following an examination as to whether Jardiance (empagliflozin) offers an added benefit over appropriate comparator therapies, the German health cost advisory agency, the Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that an added benefit was not proven.

Produced by German family-owned drug major Boehringer Ingelheim and partner USA-based Eli Lilly (NYSE: LLY), Jardiance has been approved in Europe since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycemic control.

For four of five research questions, the manufacturer presented no relevant data in its dossier, says the IQWiG. For the fifth research question, on the one hand, it presented data from a direct comparison, in which empagliflozin was initially administered at a larger dose than recommended by the approval.